The Impact of Alcohol Use on Tuberculosis Treatment Outcomes: a Systematic Review and Meta-analysis

Overview

Journal Int J Tuberc Lung Dis

Specialty Pulmonary Medicine

Date 2020 Feb 2

PMID 32005309

Citations 39

Authors

E J Ragan

M B Kleinman

B Sweigart

N Gnatienko

C D Parry

C R Horsburgh

M P LaValley

B Myers

K R Jacobson

Affiliations

Soon will be listed here.

Abstract

Alcohol use is associated with increased risk of developing tuberculosis (TB) disease, yet the impact of alcohol use on TB treatment outcomes has not been summarized. We aimed to quantitatively review evidence of the relationship between alcohol use and poor TB treatment outcomes. We conducted a systematic review of PubMed, EMBASE, and Web of Science (January 1980-May 2018). We categorized studies as having a high- or low-quality alcohol use definition and examined poor treatment outcomes individually and as two aggregated definitions (i.e., including or excluding loss to follow-up [LTFU]). We analyzed drug-susceptible (DS-) and multidrug-resistant (MDR-) TB studies separately. Our systematic review yielded 111 studies reporting alcohol use as a predictor of DS- and MDR-TB treatment outcomes. Alcohol use was associated with increased odds of poor treatment outcomes (i.e., death, treatment failure, and LTFU) in DS (OR 1.99, 95% CI 1.57-2.51) and MDR-TB studies (OR 2.00, 95% CI 1.73-2.32). This association persisted for aggregated poor treatment outcomes excluding LTFU, each individual poor outcome, and across sub-group and sensitivity analyses. Only 19% of studies used high-quality alcohol definitions. Alcohol use significantly increased the risk of poor treatment outcomes in both DS- and MDR-TB patients. This study highlights the need for improved assessment of alcohol use in TB outcomes research and potentially modified treatment guidelines for TB patients who consume alcohol.

Citing Articles

Prevalence of extrapulmonary tuberculosis and factors influencing successful treatment outcomes among notified cases in South India.

VidyaRaj C, Vadakunnel M, Mani B, Anbazhagi M, Pradhabane G, Venkateswari R Sci Rep. 2025; 15(1):8290.

PMID: 40065047 PMC: 11893790. DOI: 10.1038/s41598-025-92613-5.

Alcohol use disorder among people diagnosed with tuberculosis in a large urban case-finding project in central Uganda: prevalence, associated factors and challenges to treatment adherence.

Bayigga J, Kakai I, Odongpiny E, Ddungu A, Semakula L, Nansereko M Subst Abuse Treat Prev Policy. 2025; 20(1):10.

PMID: 40045303 PMC: 11881283. DOI: 10.1186/s13011-024-00629-3.

Integrating narrative and bibliometric approaches to examine factors and impacts of tuberculosis treatment non-compliance.

Santosa A, Juniarti N, Pahria T, Susanti R Multidiscip Respir Med. 2025; 20.

PMID: 40017294 PMC: 11875689. DOI: 10.5826/mrm.2025.1016.

Determinants of unfavourable treatment outcomes of drug-resistant tuberculosis cases in Malaysia: a case-control study.

Kamarul Zaman M, Nik Husain N, Sidek M, Abu Bakar Z BMJ Open. 2025; 15(2):e093391.

PMID: 39965941 PMC: 11836788. DOI: 10.1136/bmjopen-2024-093391.

Effect of Vitamin D Supplementation on the Treatment of Pulmonary Tuberculosis Patients in Different Polymorphisms of the Vitamin D Receptor.

Bavi H, Hosseini S, Ekrami A, Alavi S, Malehi A Adv Biomed Res. 2024; 13:102.

PMID: 39717253 PMC: 11665168. DOI: 10.4103/abr.abr_76_24.

References

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Baujat B, Mahe C, Pignon J, Hill C . A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002; 21(18):2641-52. DOI: 10.1002/sim.1221. View

Gelmanova I, Keshavjee S, Golubchikova V, Berezina V, Strelis A, Yanova G . Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ. 2007; 85(9):703-11. PMC: 2636414. DOI: 10.2471/blt.06.038331. View

Miller A, Gelmanova I, Keshavjee S, Atwood S, Yanova G, Mishustin S . Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation. Int J Tuberc Lung Dis. 2012; 16(7):891-6. PMC: 8324013. DOI: 10.5588/ijtld.11.0795. View

Imtiaz S, Shield K, Roerecke M, Samokhvalov A, Lonnroth K, Rehm J . Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. Eur Respir J. 2017; 50(1). PMC: 5540679. DOI: 10.1183/13993003.00216-2017. View

Huangfu P, Pearson F, Ugarte-Gil C, Critchley J . Diabetes and poor tuberculosis treatment outcomes: issues and implications in data interpretation and analysis. Int J Tuberc Lung Dis. 2018; 21(12):1214-1219. DOI: 10.5588/ijtld.17.0211. View

Peltzer K, Louw J, Mchunu G, Naidoo P, Matseke G, Tutshana B . Hazardous and harmful alcohol use and associated factors in tuberculosis public primary care patients in South Africa. Int J Environ Res Public Health. 2012; 9(9):3245-57. PMC: 3499864. DOI: 10.3390/ijerph9093245. View

Kurbatova E, Taylor A, Gammino V, Bayona J, Becerra M, Danilovitz M . Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis (Edinb). 2012; 92(5):397-403. PMC: 4749016. DOI: 10.1016/j.tube.2012.06.003. View

Shin S, Mathew T, Yanova G, Fitzmaurice G, Livchits V, Yanov S . Alcohol consumption among men and women with tuberculosis in Tomsk, Russia. Cent Eur J Public Health. 2010; 18(3):132-8. PMC: 3062936. DOI: 10.21101/cejph.a3590. View

10.

Bajunirwe F, Haberer J, Boum 2nd Y, Hunt P, Mocello R, Martin J . Comparison of self-reported alcohol consumption to phosphatidylethanol measurement among HIV-infected patients initiating antiretroviral treatment in southwestern Uganda. PLoS One. 2014; 9(12):e113152. PMC: 4249861. DOI: 10.1371/journal.pone.0113152. View

11.

Khan F, Minion J, Al-Motairi A, Benedetti A, Harries A, Menzies D . An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis. 2012; 55(8):1154-63. DOI: 10.1093/cid/cis630. View

12.

Saunders J, Aasland O, Babor T, De la Fuente J, Grant M . Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993; 88(6):791-804. DOI: 10.1111/j.1360-0443.1993.tb02093.x. View

13.

Saukkonen J, Cohn D, Jasmer R, Schenker S, Jereb J, Nolan C . An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174(8):935-52. DOI: 10.1164/rccm.200510-1666ST. View

14.

Jakubowiak W, Bogorodskaya E, Borisov S, Borisov E, Danilova I, Danilova D . Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis. 2007; 11(1):46-53. View

15.

Garrido M, Penna M, Perez-Porcuna T, de Souza A, Marreiro L, Albuquerque B . Factors associated with tuberculosis treatment default in an endemic area of the Brazilian Amazon: a case control-study. PLoS One. 2012; 7(6):e39134. PMC: 3373579. DOI: 10.1371/journal.pone.0039134. View

16.

Rehm J, Samokhvalov A, Neuman M, Room R, Parry C, Lonnroth K . The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009; 9:450. PMC: 2796667. DOI: 10.1186/1471-2458-9-450. View

17.

Volkmann T, Moonan P, Miramontes R, Oeltmann J . Tuberculosis and excess alcohol use in the United States, 1997-2012. Int J Tuberc Lung Dis. 2014; 19(1):111-9. PMC: 4798229. DOI: 10.5588/ijtld.14.0516. View

18.

Koriakin V, Sokolova G, Grinchar N, Iurchenko L . [Pharmacokinetics of isoniazid in patients with pulmonary tuberculosis and alcoholism]. Probl Tuberk. 1986; (12):43-6. View

19.

. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017; 18(3):261-284. PMC: 5831985. DOI: 10.1016/S1473-3099(17)30703-X. View

20.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2011; 3(3):e123-30. PMC: 3090117. View